[1] Tian, Yange, Jiansheng, et al. Effects of therapies for regulating and reinforcing lung and kidney on osteoporosis in rats with chronic obstructive pulmonary disease[J]. Journal of Traditional Chinese Medicine,2015,35(2): 175-183. [2] 郭洁, 武蕾, 田振峰,等. 温肾化痰配方颗粒对COPD稳定期患者肺功能与生活质量的影响[J]. 南京中医药大学学报,2013, 29(6): 596-8. [3] Knobloch J, Wahl C, Feldmann M, et al. Resveratrol Attenuates the Release of Inflammatory Cytokines from Human Bronchial Smooth Muscle Cells Exposed to Lipoteichoic Acid in Chronic Obstructive Pulmonary Disease[J]. Basic & Clinical Pharmacology & Toxicology, 2014,114(2): 202-209. [4] Zhang L, Su Z, Zhang Z, et al. Effects of Azithromycin on Gene Expression Profiles of Proinflammatory and Anti-inflammatory Mediators in the Eyelid Margin and Conjunctiva of Patients With Meibomian Gland Disease[J]. Jama Ophthalmology,2015,133(10): 1329-1334. [5] 殷少军. 用最新指南指导老年COPD诊治[C]// 全国老年医学进展学术会议暨江苏省中西医结合学会老年分会学术年会.江苏:江苏省中西医结合学会老年分会,2015. [6] 牟江, 桂天绪, 万礼,等. 沙美特罗替卡松粉吸入剂治疗中度COPD稳定期的临床研究[J]. 临床肺科杂志,2014,19(3): 444-447. [7] Giamarellos-Bourboulis E J. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators[J]. International Journal of Antimicrobial Agents,2008,31(1): 12-20. [8] 欧立文, 卢平. 低剂量阿奇霉素对慢性阻塞性肺疾病稳定期患者气道中肿瘤坏死因子-α的影响及疗效[J]. 中国老年学杂志, 2014,34(3): 656. [9] 赵仁国, 张鸣华, 慈晓,等. 阿奇霉素对慢性阻塞性肺疾病稳定期患者肺功能及细胞因子的影响[J]. 浙江实用医学,2013, 18(6): 388-390. [10] Uzun S, Djamin R S, Kluytmans J, et al. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): Study protocol for a randomised controlled trial[J]. Trials,2012,13(1): 1-7. [11] Hodge S, Hodge G, Holmes M, et al. Increased CD8 T‐cell granzyme B in COPD is suppressed by treatment with low‐dose azithromycin[J]. Respirology,2015,20(1): 95-100. [12] 吴心宏, 樊昊. 长期小剂量阿奇霉素治疗稳定期 COPD 的临床疗效观察[J]. 临床肺科杂志,2013,18(4): 649-651. [13] Woodruff P G, Chatila W, Connett J E, et al. Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial[J]. European Respiratory Journal,2014,43(1): 295-298. [14] Han M L K, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy[J]. American journal of respiratory and critical care medicine,2014,189(12): 1503-1508. [15] Wan Y, Huang Z, Jing K, et al. Azithromycin Attenuates Pulmonary Inflammation and Emphysema in Smoking-Induced COPD Model in Rats[J]. Respiratory care,2015,60(1): 128-134. |